Back to ChemicalBook Home--->CAS DataBase List--->112809-51-5

112809-51-5

112809-51-5 Structure

112809-51-5 Structure
IdentificationMore
[Name]

Letrozole
[CAS]

112809-51-5
[Synonyms]

4,4'-(1H-1,2,4-TRIAZOL-1-YLMETHYLENE) BIS-BENZONITRILE
CGS-20267
FEMARA
LETROZOL
LETROZOLE
LetrozoleUsp28
Letrozole99%
CGS-20267, Femara
LETRAZOLE
letrozolex
Lelrozol
1-[BIS(4-CYANOPHENYL)METHYL]-1,2,4-TRIAZOLE
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazole-1-ylmethylene)bisbenzonitrile
4,4'-[(1H-1,2,4-Triazole-1-yl)methylene]dibenzonitrile
[Molecular Formula]

C17H11N5
[MDL Number]

MFCD00866241
[Molecular Weight]

285.3
[MOL File]

112809-51-5.mol
Chemical PropertiesBack Directory
[Appearance]

white to off-whitecrystalline powder
[Features]

Letrozole(112809-51-5) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer.
[mp ]

181-183°C
[Usage]

A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic
[CAS DataBase Reference]

112809-51-5(CAS DataBase Reference)
[FDA-approved use]

Letrozole(112809-51-5) is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medications such as bisphosphonates.
Safety DataBack Directory
[Hazard Codes ]

Xi
[Risk Statements ]

R36/37/38:Irritating to eyes, respiratory system and skin .
[Safety Statements ]

S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing .
[HS Code ]

2933997500
[Hazardous Substances Data]

112809-51-5(Hazardous Substances Data)
Raw materials And Preparation ProductsBack Directory
【Raw materials】

Potassium tert-butoxide-->3-Amino-5-mercapto-1,2,4-triazole-->4-Cyanobenzyl bromide
Material Safety Data Sheet(MSDS)Back Directory
[msds information]

4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile(112809-51-5).msds
Questions and Answers (Q&A)Back Directory
[Description]

Letrozole (trade name: Femara) is an orally active nonsteroidal aromatase inhibitor. As a competitive inhibitor of the aromatase, Letrozole inhibits the conversion of androgens to estrogen (estrogen stimulates breast tissues and breast cancer reoccurrence) and gonadal steroidogenesis. It can be used for the treatment of breast cancer that is hormonally-responsive or has an unknown receptor status in postmenopausal women. Besides this, Letrozole also has some off-label use such as ovarian stimulation, pretreatment of termination of pregnancy, treatment of gynecomastia, treatment of endometriosis, and promoting spermatogenesis for male patients of nonobstructive azoospermia.
[References]

https://www.drugbank.ca/drugs/DB01006
https://en.wikipedia.org/wiki/Letrozole
Questions And AnswerBack Directory
[Indications and uses]

Letrozole is part of a new generation of highly selective aromatase inhibitors and is an artificially synthesized benzotriazole derivative. Letrozole inhibits aromatase to lower estrogen levels, thus preventing estrogen from stimulating tumor growth. Its in vivo activity is 150-250 times stronger than that of first generation aromatase inhibitor Amarante. As it is highly selective, it will not impact glucocorticoid, mineralocorticoid and thyroid functions; even at high dosages, it will not have any inhibiting effects on adrenal corticosteroid secretion, giving it a high treatment index. Letrozole has no latent toxicity towards any bodily systems and target organs, has no mutagenicity and carcinogenic effects, has minimal toxic side effects, is well-tolerated, and has stronger anticancer effects than other aromatase inhibitors and antiestrogen drugs. Letrozole is suitable for advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment and for early breast cancer treatment. It is used to treat postmenopausal patients with advanced breast cancer and serves as a second-line treatment to follow unsuccessful antiestrogen treatment. Compared to the current standard Tamoxifen treatment, Letrozole can better prevent the risk of breast cancer recurrence.
[Pharmacokinetics]

Absorption of oral letrozole is rapid and complete and steady state is achieved in 2–6 weeks with administration of letrozole 2.5mg once daily. The major route of elimination of letrozole is via metabolism to a pharmacologically inactive carbinol metabolite. The cytochrome P450 (CYP) 3A4 and CYP2A6 isozymes metabolize letrozole to a pharmacologically inactive carbinol metabolite. Renal excretion of a glucuronide conjugate of the carbinol metabolite of letrozole represents the major route of drug clearance.

[Side effects]

Randomized grouping studies have shown that daily oral ingestion of 2.5mg Letrozole leads to a 33% rate of drug-related negative reactions, a percentage much lower than AG group’s 46%. Negative reactions to Letrozole are mostly mild or moderate, consisting mostly of nausea (2-9%), headache (0-7%), bone pain (4-10%), hot flashes (0-9%) and weight gain (2-8%). Other uncommon side effects include constipation, diarrhea, itching, rash, joint pain, chest pain, abdominal pain, fatigue, insomnia, dizziness, edema, high blood pressure, arrhythmia, thrombosis, dyspnea, vaginal bleeding, etc.
112809-51-5 suppliers list
Company Name: Beijing Yibai Biotechnology Co., Ltd
Tel: 0086-182-6772-3597
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList187389/0.htm
Company Name: Amadis Chemical Company Limited
Tel: 0086-571-89925085
Fax: 0086-571-89925065
Website: www.amadischem.com
Company Name: Shenzhen Nexconn Pharmatechs Ltd
Tel: 15013857715
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList31188/0.htm
Company Name: GIHI CHEMICALS CO.,LIMITED
Tel: 08657186217390
Fax:
Website: www.gihichemicals.com
Company Name: SIMAGCHEM CORP
Tel: +86 13806087780
Fax:
Website: www.simagchem.com
Company Name: Chemwill Asia Co.,Ltd.
Tel: 86-21-51086038
Fax: 86-21-51861608
Website: www.chemwill.com
Company Name: HaBo Hong Kong Co., Limited.
Tel: +86-25-18512596065
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList31287/0.htm
Company Name: Cangzhou Wanyou New Material Technology Co.,Ltd
Tel: 18631714998
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1382651/0.htm
Company Name: Shanghai Worldyang Chemical Co.,Ltd.
Tel: +86-13651600618,+86-21-56795779
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1875604/0.htm
Company Name: Xiamen AmoyChem Co., Ltd
Tel: +86 592-605 1114
Fax:
Website: www.amoychem.com
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Fax: 027-59338440
Website: www.chemicalbook.com/ShowSupplierProductsList1549548/0.htm
Company Name: Shanghai Longyu Biotechnology Co., Ltd.
Tel: +8615821988213
Fax:
Website: www.chemicalbook.com/manufacturer/ExhibitionBooth164/
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-13650506873
Fax:
Website: www.chemdad.com
Company Name: Shenzhen Excellent Biotech Co., Ltd.
Tel: 13480692018
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1588779/0.htm
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: 86-18523575427
Fax:
Website: https://www.chemicalbook.com/ShowSupplierProductsList617604/0.htm
Company Name: Shaanxi Dideu Medichem Co. Ltd
Tel: +86-15319487004
Fax: +86-29-88380327
Website: https://www.chemicalbook.com/ShowSupplierProductsList715900/0.htm
Company Name: Zhuozhou Wenxi import and Export Co., Ltd
Tel: +8613111626072
Fax: +8613111626072
Website: https://www.chemicalbook.com/ShowSupplierProductsList403210/0.htm
Company Name: Qingdao kaimoshi biochemical technology co., ltd.
Tel: +(86) 571 8719 1975
Fax: +(86) 571 8719 1975
Website: www.kaimosi.com
Tags:112809-51-5 Related Product Information
136572-09-3 138926-19-9 120511-73-1 25332-39-2 2440-22-4 19794-93-5 120511-84-4 120511-72-0 134521-16-7 120511-74-2 112809-25-3 10406-25-4 112809-51-5 136-85-6 768-33-2 29385-43-1 288-88-0 95-14-7